Novartis Ag Stock News

Basel, December 8, 2021 Novartis today announced new Kisqali ® (ribociclib) data demonstrating a consistent overall survival (OS) benefit with Kisqali plus endocrine therapy (ET) across genomic subtypes of hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer (mBC), similarly in the indolent as well as in the aggressive, endocrine therapy (ET)-resistant subtypes 6 . The findings will be presented as a late-breaking oral presentation at the 2021 San Antonio Breast Cancer Symposium (SABCS).

13. Prat, A. et al. Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy. BMC Med. 13, 1--11 (2015). 14. Llombart-Cussac, A. et al. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without

Ranibizumab Market research report presents the company profile, product specifications, capacity, production value, and 2021-2026 market shares for each company. This market analysis report is generated with the best and advanced tools for collecting, recording, estimating, and analyzing market data.

Novartis AG (NYSE: NVS) shared new data from the MONALEESA Phase 3 program of Kisqali (ribociclib), the CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer and proven overall survival (OS) benef

The latest analysis released by HTF MI on "Global Antifungal Drugs Market Outlook 2020 Survey results" sheds light on how investment and competitive landscape is impacted due to significant changes in the Antifungal Drugs Industry. The research coverage includes analysis

The global Oncology Drugs market is expected to reach US$ 362.4 Billion by 2027, with a CAGR of 12.4% from 2021 to 2027. The rise in the prevalence of cancer disease and the incidence of various cancer conditions, as well

DUBLIN--(BUSINESS WIRE)--The "Breast Cancer Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com''s offering. The global breast cancer monoclonal antibodies market is expected to grow from $12.67 billion in 2020 to $13.76 billion in 2021 at a compound annual growth rate (CAGR) of 8.6%. The market is expected to reach $18.61 billion in 2025 at a CAGR of 8%. Major players in the breast cancer monoclonal antibodies (mAb

The global Peripheral Neuropathy Treatment market is expected a CAGR of 5.8% from 2021 to 2027. Major players are concentrating their efforts on developing drugs to treat peripheral neuropathy, which is expected to drive market growth during the forecast period.

Novartis (NYSE:NVS) was downgraded by research analysts at BNP Paribas from an outperform rating to a neutral rating in a note issued to investors on Monday, Price Targets.com reports. Several other equities research analysts have also recently weighed in on the company. Berenberg Bank reissued a buy rating on shares of Novartis in a research []

Novartis (NYSE:NVS) was downgraded by Exane BNP Paribas from an outperform rating to a neutral rating in a report issued on Monday, The Fly reports. They presently have a CHF 85 price target on the stock. Other equities research analysts have also recently issued research reports about the company. Deutsche Bank Aktiengesellschaft cut Novartis from []

Leukemia Therapeutics Market Snapshot: The Global Leukemia Therapeutics Market is expected to grow at a steady growth during the forecast period 2019-2029, Leukemia Therapeutics Market report offers insights into the latest trends. It summarizes key aspects of the market, with a

DUBLIN--(BUSINESS WIRE)--The "Dementia - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com''s offering. The clinical trial report provides an overview of Dementia Clinical trials scenario. This report provides top line data relating to the clinical trials on Dementia . The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by re

DUBLIN, Dec. 7, 2021 /PRNewswire/ -- The "The Pharmaceutical Cannabis Report: 2nd Edition" report has been added to ResearchAndMarkets.com''s offering. The author estimates the market size for the three most widely used cannabinoid pharmaceuticals (Epidiolex , Sativex , dronabinol) to be…

DUBLIN--(BUSINESS WIRE)--The "Immunosuppressants Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com''s offering. The global immunosuppressants market is expected to grow from $15.04 billion in 2020 to $16.5 billion in 2021 at a compound annual growth rate (CAGR) of 9.7%. The market is expected to reach $25.33 billion in 2025 at a CAGR of 11%. Major players in the immunosuppressant market are Astellas Pharma, GlaxoSmithKline, Bristol Mye

DUBLIN--(BUSINESS WIRE)--The "Psoriatic Arthritis Treatment Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com''s offering. The global psoriatic arthritis treatment market is expected to grow from $7.26 billion in 2020 to $7.89 billion in 2021 at a compound annual growth rate (CAGR) of 8.7%. The market is expected to reach $11.34 billion in 2025 at a CAGR of 9%. Major players in the psoriatic arthritis treatment market are AbbVie, Amgen